Belgian Cancer Registry

CANCER FACT SHEET 2024

MELANOMA

ICD-10 C43



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Belgian Cancer Registry

TABLE OF CONTENTS



1. CANCER INCIDENCE 5

1.1. Melanoma incidence: by region 5

1.1.1. Melanoma incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Melanoma incidence: by tumour stage 7

1.2.1. Melanoma incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.2. Melanoma incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.3. Melanoma incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.2.4. Melanoma incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

1.2.5. Melanoma incidence by pT sub-categories, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 11

2. CANCER INCIDENCE TRENDS 12

2.1. Melanoma incidence trends: by region 12

2.1.1. Melanoma incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

2.1.2. Melanoma incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 14

2.2. Melanoma incidence trends: by tumour stage 15

2.2.1. Melanoma incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 15

2.3. Melanoma incidence trends: by age group 17

2.3.1. Melanoma incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 17

2.3.2. Melanoma incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 18

3. CANCER PREVALENCE 19

3.1. Melanoma prevalence: by region 19

3.1.1. Melanoma prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 19

4. CANCER SURVIVAL 20

4.1. Melanoma survival: by region 20

4.1.1. Melanoma survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 20

4.2. Melanoma survival: by tumour stage 22

4.2.1. Melanoma survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024 22

4.2.2. Melanoma survival by pathological stage (pStage) and sex: number at risk and net survival probabilities, 2015-2024 23

4.2.3. Melanoma survival by stage and sex: number at risk and net survival probabilities, 2015-2024 24
5. CANCER SURVIVAL TRENDS 25
5.1. Melanoma survival trends: by tumour stage 25
5.1.1. Melanoma survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024 25
6. CANCER MORTALITY 27
6.1. Melanoma mortality: by region 27
6.1.1. Melanoma mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 27
7. CANCER MORTALITY TRENDS 29
7.1. Melanoma mortality trends: by region 29
7.1.1. Melanoma mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 29
7.1.2. Melanoma mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 31

1.1. Melanoma incidence: by region

1.1.1. Melanoma incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	2	4	11	35	53	80	100	159	204	265	251	262	276	178	106	36	7	2,029	36.4
	[0.0]	[0.0]	[0.0]	[0.6]	[1.2]	[3.0]	[9.0]	[13.9]	[20.8]	[26.8]	[40.5]	[51.2]	[69.7]	[77.3]	[97.5]	[129.6]	[140.7]	[129.0]	[110.4]	[109.8]	[35.0]	(34.8; 38.0)
Brussels	0	0	0	0	0	2	4	4	8	12	14	10	19	11	19	24	15	9	5	0	156	37.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.9]	[7.5]	[8.4]	[17.6]	[27.3]	[33.9]	[27.6]	[64.3]	[50.6]	[111.9]	[186.5]	[182.3]	[177.7]	[222.7]	[0.0]	[25.5]	(31.2; 43.4)
Flanders	0	0	0	2	3	6	22	26	46	57	104	146	165	166	169	189	127	79	23	3	1,333	38.8
	[0.0]	[0.0]	[0.0]	[1.0]	[1.6]	[3.0]	[10.1]	[12.2]	[20.7]	[26.8]	[46.0]	[61.1]	[71.0]	[82.7]	[101.8]	[139.9]	[151.6]	[142.0]	[105.2]	[71.3]	[39.5]	(36.7; 40.8)
Wallonia	0	0	0	0	1	3	9	23	26	31	41	48	81	74	74	63	36	18	8	4	540	31.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.7]	[7.6]	[19.4]	[22.2]	[26.6]	[32.6]	[38.9]	[68.6]	[72.3]	[86.5]	[96.9]	[104.2]	[83.9]	[94.3]	[249.4]	[29.9]	(29.0; 34.4)
Females																						
Belgium	1	0	0	8	14	33	68	88	120	166	244	276	271	245	223	191	138	96	60	14	2,256	36.7
	[0.3]	[0.0]	[0.0]	[2.4]	[4.2]	[9.1]	[17.4]	[22.9]	[31.1]	[44.9]	[63.3]	[70.3]	[70.2]	[71.0]	[74.7]	[74.6]	[79.4]	[70.8]	[83.3]	[64.8]	[37.8]	(35.2; 38.2)
Brussels	0	0	0	1	0	1	8	3	5	13	15	9	14	20	16	10	18	6	4	0	143	27.0
	[0.0]	[0.0]	[0.0]	[2.7]	[0.0]	[1.8]	[14.7]	[6.2]	[11.0]	[31.1]	[38.9]	[26.2]	[45.8]	[79.5]	[74.3]	[53.9]	[140.5]	[62.2]	[70.9]	[0.0]	[22.4]	(22.5; 31.5)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	1	0	0	3	9	21	47	61	84	113	161	192	183	168	149	133	90	74	39	9	1,537	42.3
	[0.6]	[0.0]	[0.0]	[1.6]	[4.9]	[10.6]	[21.5]	[28.3]	[37.8]	[53.6]	[72.7]	[82.4]	[79.0]	[81.3]	[84.1]	[86.0]	[82.1]	[85.3]	[86.1]	[69.9]	[44.6]	(40.1; 44.4)
Wallonia	0	0	0	4	5	11	13	24	31	40	68	75	74	57	58	48	30	16	17	5	576	29.6
	[0.0]	[0.0]	[0.0]	[3.6]	[4.6]	[10.3]	[11.0]	[20.0]	[26.2]	[34.2]	[54.2]	[59.9]	[59.8]	[50.4]	[58.1]	[58.0]	[58.3]	[40.9]	[80.5]	[75.4]	[30.6]	(27.1; 32.0)

1.2. Melanoma incidence: by tumour stage

1.2.1. Melanoma incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages 0+		15-49	50-64	65+	All ages 0+	
I	236 [9.1]	521 [44.5]	772 [73.2]	1,529 [26.4]	27.2 (25.9; 28.6)	444 [17.3]	691 [59.4]	662 [50.8]	1,797 [30.1]	29.7 (28.3; 31.1)
II	30 [1.2]	72 [6.1]	262 [24.9]	364 [6.3]	6.7 (6.0; 7.3)	41 [1.6]	66 [5.7]	227 [17.4]	335 [5.6]	5.1 (4.5; 5.6)
III	4 [0.2]	4 [0.3]	20 [1.9]	28 [0.5]	0.5 (0.3; 0.7)	2 [0.1]	8 [0.7]	20 [1.5]	30 [0.5]	0.5 (0.3; 0.6)
IV	3 [0.1]	6 [0.5]	21 [2.0]	30 [0.5]	0.6 (0.4; 0.8)	3 [0.1]	4 [0.3]	22 [1.7]	29 [0.5]	0.4 (0.3; 0.6)
X/NA	12 [0.5]	25 [2.1]	41 [3.9]	78 [1.3]	1.4 (1.1; 1.7)	7 [0.3]	22 [1.9]	36 [2.8]	65 [1.1]	1.0 (0.8; 1.2)

1.2.2. Melanoma incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages 0+		15-49	50-64	65+	All ages 0+	
I	228 [8.8]	504 [43.0]	765 [72.6]	1,497 [25.8]	26.7 (25.3; 28.1)	425 [16.6]	674 [57.9]	649 [49.8]	1,748 [29.3]	28.9 (27.5; 30.3)
II	21 [0.8]	50 [4.3]	237 [22.5]	308 [5.3]	5.7 (5.1; 6.4)	32 [1.2]	56 [4.8]	204 [15.7]	292 [4.9]	4.4 (3.9; 4.9)
III	23 [0.9]	44 [3.8]	63 [6.0]	130 [2.2]	2.3 (1.9; 2.7)	31 [1.2]	36 [3.1]	62 [4.8]	130 [2.2]	2.1 (1.7; 2.5)
IV	2 [0.1]	2 [0.2]	4 [0.4]	8 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	1 [0.1]	7 [0.5]	9 [0.2]	0.1 (0.0; 0.2)
X/NA	11 [0.4]	28 [2.4]	47 [4.5]	86 [1.5]	1.5 (1.2; 1.9)	8 [0.3]	24 [2.1]	45 [3.5]	77 [1.3]	1.2 (0.9; 1.4)

1.2.3. Melanoma incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages 0+		15-49	50-64	65+	All ages 0+	
I	226 [8.7]	503 [42.9]	763 [72.4]	1,492 [25.7]	26.6 (25.2; 28.0)	424 [16.5]	673 [57.8]	648 [49.7]	1,745 [29.2]	28.8 (27.5; 30.2)
II	21 [0.8]	49 [4.2]	230 [21.8]	300 [5.2]	5.5 (4.9; 6.2)	31 [1.2]	55 [4.7]	195 [15.0]	281 [4.7]	4.2 (3.7; 4.7)
III	23 [0.9]	44 [3.8]	61 [5.8]	128 [2.2]	2.3 (1.9; 2.6)	32 [1.2]	36 [3.1]	63 [4.8]	132 [2.2]	2.1 (1.8; 2.5)
IV	4 [0.2]	8 [0.7]	22 [2.1]	34 [0.6]	0.6 (0.4; 0.9)	3 [0.1]	5 [0.4]	25 [1.9]	33 [0.6]	0.5 (0.3; 0.7)
X/NA	11 [0.4]	24 [2.0]	40 [3.8]	75 [1.3]	1.3 (1.0; 1.6)	7 [0.3]	22 [1.9]	36 [2.8]	65 [1.1]	1.0 (0.8; 1.2)

1.2.4. Melanoma incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Sub-locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-64	65+	All ages 0+		15-49	50-64	65+	All ages 0+	
Head	**All**	47 [1.8]	84 [7.2]	284 [26.9]	415 [7.2]	7.6 (6.9; 8.4)	35 [1.4]	54 [4.6]	160 [12.3]	249 [4.2]	3.8 (3.3; 4.3)
	I	39 [1.5]	68 [5.8]	183 [17.4]	290 [5.0]	5.3 (4.7; 5.9)	28 [1.1]	48 [4.1]	100 [7.7]	176 [2.9]	2.8 (2.4; 3.2)
	II	4 [0.2]	7 [0.6]	78 [7.4]	89 [1.5]	1.7 (1.3; 2.0)	5 [0.2]	4 [0.3]	43 [3.3]	52 [0.9]	0.7 (0.5; 0.9)
	III	3 [0.1]	8 [0.7]	15 [1.4]	26 [0.4]	0.5 (0.3; 0.7)	2 [0.1]	1 [0.1]	9 [0.7]	12 [0.2]	0.2 (0.1; 0.3)
	IV	0 [0.0]	0 [0.0]	5 [0.5]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	5 [0.4]	5 [0.1]	0.1 (0.0; 0.1)
	X/NA	1 [0.0]	1 [0.1]	3 [0.3]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	1 [0.1]	3 [0.2]	4 [0.1]	0.0 (0.0; 0.1)
Trunk	**All**	112 [4.3]	308 [26.3]	446 [42.3]	866 [14.9]	15.4 (14.4; 16.4)	144 [5.6]	236 [20.3]	195 [15.0]	575 [9.6]	9.6 (8.8; 10.3)
	I	90 [3.5]	265 [22.6]	337 [32.0]	692 [11.9]	12.2 (11.3; 13.2)	119 [4.6]	196 [16.8]	143 [11.0]	458 [7.7]	7.7 (6.9; 8.4)
	II	10 [0.4]	21 [1.8]	78 [7.4]	109 [1.9]	2.0 (1.6; 2.4)	11 [0.4]	21 [1.8]	33 [2.5]	65 [1.1]	1.1 (0.8; 1.3)
	III	11 [0.4]	17 [1.5]	21 [2.0]	49 [0.8]	0.9 (0.6; 1.1)	12 [0.5]	16 [1.4]	12 [0.9]	40 [0.7]	0.7 (0.5; 0.9)
	IV	1 [0.0]	5 [0.4]	7 [0.7]	13 [0.2]	0.2 (0.1; 0.4)	2 [0.1]	2 [0.2]	6 [0.5]	10 [0.2]	0.2 (0.1; 0.3)
	X/NA	0 [0.0]	0 [0.0]	3 [0.3]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	1 [0.1]	1 [0.1]	2 [0.0]	0.0 (0.0; 0.1)
Upper limb	**All**	57 [2.2]	120 [10.2]	237 [22.5]	414 [7.1]	7.4 (6.7; 8.1)	106 [4.1]	191 [16.4]	268 [20.6]	566 [9.5]	9.1 (8.4; 9.9)
	I	47 [1.8]	103 [8.8]	168 [15.9]	318 [5.5]	5.7 (5.0; 6.3)	95 [3.7]	175 [15.0]	186 [14.3]	456 [7.6]	7.5 (6.8; 8.2)
	II	7 [0.3]	8 [0.7]	52 [4.9]	67 [1.2]	1.2 (0.9; 1.5)	5 [0.2]	8 [0.7]	59 [4.5]	72 [1.2]	1.0 (0.8; 1.3)
	III	2 [0.1]	7 [0.6]	12 [1.1]	21 [0.4]	0.4 (0.2; 0.5)	5 [0.2]	5 [0.4]	18 [1.4]	29 [0.5]	0.5 (0.3; 0.6)
	IV	1 [0.0]	2 [0.2]	3 [0.3]	6 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	1 [0.1]	4 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
	X/NA	0 [0.0]	0 [0.0]	2 [0.2]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	2 [0.2]	1 [0.1]	3 [0.1]	0.0 (0.0; 0.1)
Lower limb	**All**	59 [2.3]	88 [7.5]	117 [11.1]	264 [4.6]	4.7 (4.1; 5.3)	205 [8.0]	291 [25.0]	312 [24.0]	808 [13.5]	13.3 (12.4; 14.2)
	I	50 [1.9]	64 [5.5]	74 [7.0]	188 [3.2]	3.3 (2.8; 3.8)	181 [7.1]	252 [21.6]	219 [16.8]	652 [10.9]	10.9 (10.0; 11.7)
	II	0 [0.0]	13 [1.1]	22 [2.1]	35 [0.6]	0.6 (0.4; 0.8)	10 [0.4]	22 [1.9]	60 [4.6]	92 [1.5]	1.4 (1.1; 1.7)

Sub-locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-64	65+	All ages 0+		15-49	50-64	65+	All ages 0+	
	III	7 [0.3]	11 [0.9]	13 [1.2]	31 [0.5]	0.5 (0.4; 0.7)	13 [0.5]	14 [1.2]	24 [1.8]	51 [0.9]	0.8 (0.6; 1.1)
	IV	2 [0.1]	0 [0.0]	6 [0.6]	8 [0.1]	0.2 (0.0; 0.3)	0 [0.0]	2 [0.2]	6 [0.5]	8 [0.1]	0.1 (0.0; 0.2)
	X/NA	0 [0.0]	0 [0.0]	2 [0.2]	2 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	1 [0.1]	3 [0.2]	5 [0.1]	0.1 (0.0; 0.1)
Overlapping sites or unspecified	All	10 [0.4]	28 [2.4]	32 [3.0]	70 [1.2]	1.2 (0.9; 1.5)	7 [0.3]	19 [1.6]	32 [2.5]	58 [1.0]	0.9 (0.7; 1.1)
	I	0 [0.0]	3 [0.3]	1 [0.1]	4 [0.1]	0.1 (0.0; 0.1)	1 [0.0]	2 [0.2]	0 [0.0]	3 [0.1]	0.0 (0.0; 0.1)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	1 [0.1]	1 [0.1]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	4 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
	X/NA	10 [0.4]	23 [2.0]	30 [2.8]	63 [1.1]	1.1 (0.8; 1.4)	6 [0.2]	17 [1.5]	28 [2.1]	51 [0.9]	0.8 (0.6; 1.0)

1.2.5. Melanoma incidence by pT sub-categories, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pT	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages 0+		15-49	50-64	65+	All ages 0+	
1	204 [7.9]	437 [37.3]	637 [60.4]	1,278 [22.0]	22.8 (21.5; 24.0)	375 [14.6]	576 [49.5]	532 [40.8]	1,483 [24.9]	24.6 (23.3; 25.9)
1a	180 [6.9]	364 [31.1]	529 [50.2]	1,073 [18.5]	19.1 (17.9; 20.2)	326 [12.7]	506 [43.5]	465 [35.7]	1,297 [21.7]	21.5 (20.4; 22.7)
1b	22 [0.8]	73 [6.2]	106 [10.1]	201 [3.5]	3.6 (3.1; 4.1)	46 [1.8]	66 [5.7]	64 [4.9]	176 [2.9]	2.9 (2.5; 3.3)
2	40 [1.5]	97 [8.3]	158 [15.0]	295 [5.1]	5.3 (4.7; 5.9)	77 [3.0]	130 [11.2]	150 [11.5]	357 [6.0]	5.8 (5.2; 6.4)
2a	34 [1.3]	84 [7.2]	136 [12.9]	254 [4.4]	4.6 (4.0; 5.1)	71 [2.8]	117 [10.1]	132 [10.1]	320 [5.4]	5.2 (4.7; 5.8)
2b	4 [0.2]	12 [1.0]	20 [1.9]	36 [0.6]	0.6 (0.4; 0.9)	6 [0.2]	12 [1.0]	17 [1.3]	35 [0.6]	0.6 (0.4; 0.8)
3	18 [0.7]	46 [3.9]	135 [12.8]	199 [3.4]	3.6 (3.1; 4.1)	30 [1.2]	40 [3.4]	110 [8.4]	181 [3.0]	2.8 (2.4; 3.2)
3a	11 [0.4]	26 [2.2]	87 [8.3]	124 [2.1]	2.3 (1.9; 2.7)	17 [0.7]	19 [1.6]	55 [4.2]	92 [1.5]	1.4 (1.1; 1.7)
3b	7 [0.3]	19 [1.6]	47 [4.5]	73 [1.3]	1.3 (1.0; 1.6)	12 [0.5]	20 [1.7]	54 [4.1]	86 [1.4]	1.3 (1.0; 1.6)
4	11 [0.4]	19 [1.6]	138 [13.1]	168 [2.9]	3.1 (2.7; 3.6)	7 [0.3]	21 [1.8]	129 [9.9]	157 [2.6]	2.3 (1.9; 2.6)
4a	7 [0.3]	7 [0.6]	48 [4.6]	62 [1.1]	1.1 (0.9; 1.4)	3 [0.1]	7 [0.6]	36 [2.8]	46 [0.8]	0.7 (0.5; 0.9)
4b	4 [0.2]	11 [0.9]	90 [8.5]	105 [1.8]	2.0 (1.6; 2.4)	4 [0.2]	14 [1.2]	88 [6.8]	106 [1.8]	1.5 (1.2; 1.8)
X/NA	12 [0.5]	29 [2.5]	48 [4.6]	89 [1.5]	1.6 (1.3; 1.9)	8 [0.3]	24 [2.1]	46 [3.5]	78 [1.3]	1.2 (0.9; 1.5)

2.1. Melanoma incidence trends: by region

2.1.1. Melanoma incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	634	632	626	733	754	730	888	946	1,091	1,099	1,199	1,202	1,283	1,467	1,552	1,664	1,664	1,713	1,897	1,990	2,029		
	CR	12.5	12.4	12.2	14.1	14.4	13.9	16.7	17.6	20.2	20.2	21.9	21.8	23.2	26.3	27.7	29.6	29.4	30.2	33.2	34.5	35.0		
	ESR2013	14.2	14.2	13.9	15.7	16.5	15.7	18.6	19.9	22.2	22.3	24.1	24.0	25.2	28.3	29.8	31.5	31.2	31.8	35.1	36.2	36.4	5.4 (5.0; 5.8)	2004-2024
																							6.0 (5.3; 6.8)	2004-2015
																							4.6 (3.7; 5.6)	2016-2024
Brussels	**N**	59	62	57	70	72	79	84	100	92	96	106	83	100	96	114	92	100	99	139	118	156		
	CR	12.3	12.8	11.6	14.1	14.2	15.3	15.9	18.4	16.6	17.1	18.7	14.5	17.2	16.5	19.4	15.5	16.7	16.5	23.2	19.4	25.5		
	ESR2013	15.3	17.1	15.9	17.7	19.4	20.3	20.8	25.4	23.6	24.3	26.0	22.0	26.0	24.7	28.5	22.9	26.7	24.6	34.8	28.0	37.3	3.4 (2.6; 4.2)	2004-2024
Flanders	**N**	373	378	387	442	426	407	478	529	634	680	725	725	773	887	983	1,085	1,109	1,169	1,281	1,342	1,333		
	CR	12.6	12.7	12.9	14.7	14.0	13.3	15.5	17.0	20.2	21.6	22.9	22.8	24.1	27.5	30.3	33.3	33.8	35.5	38.6	40.0	39.5		
	ESR2013	13.9	13.8	13.9	15.8	15.4	14.4	16.8	18.2	21.3	22.8	24.0	23.5	24.8	28.2	30.8	33.6	34.0	35.5	38.6	39.8	38.8	6.3 (5.7; 6.8)	2004-2024
Wallonia	**N**	202	192	182	221	256	244	326	317	365	323	368	394	410	484	455	487	455	445	477	530	540		
	CR	12.3	11.7	11.0	13.3	15.3	14.5	19.2	18.5	21.2	18.6	21.1	22.5	23.3	27.4	25.7	27.4	25.5	24.9	26.6	29.4	29.9		
	ESR2013	14.3	14.7	13.4	15.0	18.1	17.2	21.8	21.9	23.8	20.9	24.2	26.0	25.9	30.0	28.5	29.9	27.5	26.7	28.9	31.5	31.7	4.2 (3.7; 4.8)	2004-2024
																							6.4 (5.2; 7.5)	2004-2015

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
																						1.7 (0.3; 3.1)	2016-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Melanoma incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	885	967	978	982	1,159	1,192	1,251	1,263	1,408	1,561	1,735	1,644	1,789	1,926	1,963	2,088	1,971	2,278	2,257	2,253	2,256		
	CR	16.7	18.1	18.2	18.2	21.3	21.7	22.6	22.6	25.0	27.6	30.6	28.8	31.2	33.5	34.0	36.0	33.8	39.0	38.4	38.0	37.8		
	ESR2013	16.8	18.4	18.4	18.2	21.3	21.6	22.7	22.6	25.1	27.9	30.5	28.9	31.0	33.3	33.8	35.7	33.3	38.3	37.6	37.1	36.7	4.4 (4.0; 4.7)	2004-2024
																							5.7 (5.0; 6.5)	2004-2015
																							2.7 (1.8; 3.6)	2016-2024
Brussels	**N**	81	82	88	95	97	112	105	110	112	104	113	98	139	117	124	118	113	138	124	127	143		
	CR	15.6	15.7	16.6	17.8	17.9	20.3	18.7	19.1	19.1	17.5	18.9	16.3	22.9	19.2	20.3	19.2	18.2	22.2	19.9	20.1	22.4		
	ESR2013	16.9	16.9	18.6	19.4	18.4	21.8	21.1	20.2	22.4	19.5	21.3	18.9	26.1	21.7	24.2	22.7	21.5	25.3	23.4	24.6	27.0	1.8 (1.3; 2.4)	2004-2024
Flanders	**N**	497	558	603	579	687	720	686	699	853	997	1,059	1,048	1,086	1,215	1,289	1,417	1,315	1,561	1,581	1,565	1,537		
	CR	16.3	18.2	19.6	18.7	22.0	22.9	21.7	21.9	26.5	30.9	32.6	32.1	33.1	36.9	38.9	42.6	39.3	46.5	46.7	45.7	44.6		
	ESR2013	16.2	18.2	19.5	18.4	21.6	22.5	21.3	21.5	26.0	30.6	32.0	31.4	32.2	35.9	37.8	41.3	37.8	44.8	44.7	43.6	42.3	5.4 (4.8; 5.9)	2004-2024
																							6.4 (5.4; 7.4)	2004-2016
																							3.8 (2.3; 5.4)	2017-2024
Wallonia	**N**	307	327	287	308	375	360	460	454	443	460	563	498	564	594	550	553	543	579	552	561	576		
	CR	17.6	18.7	16.3	17.4	21.1	20.1	25.6	25.1	24.3	25.2	30.7	27.1	30.6	32.1	29.7	29.8	29.1	31.1	29.5	29.8	30.6		
	ESR2013	18.2	19.2	16.6	17.7	21.5	20.3	25.9	25.2	24.7	25.4	30.7	27.4	30.7	32.2	29.8	29.8	28.9	30.6	29.0	29.3	29.6	2.8 (2.3; 3.4)	2004-2024
																							5.4 (4.2; 6.5)	2004-2015
																							-0.2 (-1.5; 1.2)	2016-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Melanoma incidence trends: by tumour stage

2.2.1. Melanoma incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Stage		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
I	**N**	1,198	1,253	1,383	1,456	1,492			1,561	1,800	1,763	1,811	1,745		
	CR	21.2	22.1	24.2	25.3	25.7			26.8	30.8	30.0	30.5	29.2		
	ESR2013	22.2	22.9	25.2	26.2	26.6	8.4 (7.8; 9.0)	2004-2024	26.8	30.8	29.8	30.3	28.8	6.5 (5.7; 7.2)	2004-2024
							10.3 (9.1; 11.4)	2004-2016						8.7 (7.5; 9.9)	2004-2017
							5.6 (3.9; 7.4)	2017-2024						2.4 (0.1; 4.8)	2018-2024
II	**N**	247	236	290	280	300			226	294	277	241	281		
	CR	4.4	4.2	5.1	4.9	5.2			3.9	5.0	4.7	4.1	4.7		
	ESR2013	4.9	4.6	5.7	5.3	5.5	3.9 (3.3; 4.5)	2004-2024	3.5	4.5	4.3	3.6	4.2	3.0 (2.2; 3.9)	2004-2024
														5.5 (4.0; 7.0)	2004-2016
														-0.6 (-2.9; 1.7)	2017-2024
III	**N**	119	127	115	134	128			113	110	123	100	132		
	CR	2.1	2.2	2.0	2.3	2.2			1.9	1.9	2.1	1.7	2.2		
	ESR2013	2.2	2.4	2.1	2.4	2.3	5.7 (4.8; 6.5)	2004-2024	1.9	1.8	2.0	1.7	2.1	5.5 (4.4; 6.7)	2004-2024
							7.5 (5.7; 9.2)	2004-2015							
							3.5 (1.4; 5.7)	2016-2024							
IV	**N**	41	37	42	49	34			28	26	30	34	33		
	CR	0.7	0.7	0.7	0.9	0.6			0.5	0.4	0.5	0.6	0.6		
	ESR2013	0.8	0.7	0.8	0.9	0.6	2.4 (0.9; 4.0)	2004-2024	0.4	0.4	0.4	0.5	0.5	1.5 (-0.6; 3.6)	2004-2024
X/NA	**N**	59	60	67	71	75			43	48	64	67	65		
	CR	1.0	1.1	1.2	1.2	1.3			0.7	0.8	1.1	1.1	1.1		

Stage	Males							Females						
	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
ESR2013	1.1	1.2	1.3	1.3	1.3	-7.0 (-9.1; -4.8)	2004-2024	0.7	0.8	1.0	1.0	1.0	-9.9 (-12.6; -7.2)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Melanoma incidence trends: by age group

2.3.1. Melanoma incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-49	**N**	214	199	203	229	209	198	275	247	323	253	325	254	289	327	325	286	290	284	294	307	285		
	CR	8.5	7.9	8.0	9.0	8.2	7.8	10.8	9.6	12.6	9.9	12.7	10.0	11.4	12.9	12.8	11.3	11.4	11.2	11.5	11.9	11.0		
	ESR2013	8.5	7.8	8.0	9.0	8.2	7.8	10.8	9.6	12.6	9.9	12.8	10.1	11.5	13.1	13.0	11.5	11.7	11.5	11.9	12.4	11.5	2.3 (1.6; 3.1)	2004-2024
																							4.3 (2.6; 6.1)	2004-2014
																							0.4 (-1.3; 2.0)	2015-2024
50-64	**N**	168	148	170	223	230	213	259	293	334	340	354	377	399	465	490	542	572	584	563	648	628		
	CR	18.6	16.0	18.0	23.0	23.1	20.9	24.9	27.6	31.2	31.4	32.3	33.9	35.5	40.9	42.8	47.1	49.4	50.1	48.2	55.3	53.6		
	ESR2013	18.7	16.3	18.3	23.0	23.2	21.0	25.1	27.7	31.3	31.4	32.4	34.1	35.7	41.1	42.9	47.0	49.2	49.8	47.9	54.9	53.0	6.2 (5.7; 6.8)	2004-2024
65+	**N**	249	284	250	278	314	317	353	405	432	506	520	571	595	673	736	835	801	844	1,037	1,034	1,116		
	CR	33.8	38.1	33.2	36.9	41.3	41.1	45.0	50.8	52.7	60.4	60.6	65.1	66.4	73.6	78.9	87.7	82.3	85.5	102.9	100.4	105.9		
	ESR2013	34.2	38.6	34.0	36.5	42.2	41.4	45.3	51.9	53.5	60.4	61.7	65.7	66.9	73.7	79.6	87.8	83.6	86.5	104.2	102.0	107.0	6.3 (5.8; 6.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Melanoma incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-49	**N**	370	393	399	383	499	462	529	525	545	584	630	554	600	655	633	646	572	634	569	556	497		
	CR	15.0	15.9	16.1	15.4	20.0	18.5	21.1	20.9	21.6	23.2	25.1	22.1	24.0	26.3	25.4	25.9	22.9	25.4	22.7	21.9	19.4		
	ESR2013	14.9	15.8	16.1	15.4	20.0	18.5	21.2	21.0	21.8	23.4	25.3	22.3	24.4	26.6	25.8	26.3	23.2	25.9	23.2	22.4	20.0	2.0 (1.4; 2.6)	2004-2024
																							5.3 (3.6; 7.1)	2004-2012
																							4.0 (1.0; 7.1)	2013-2016
																							-2.1 (-3.8; -0.5)	2017-2024
50-64	**N**	213	251	236	280	288	331	322	306	380	443	518	511	544	569	606	692	660	760	743	718	791		
	CR	23.2	26.9	24.7	28.5	28.6	32.2	30.7	28.6	35.1	40.5	46.9	45.6	48.1	49.9	52.9	60.1	57.1	65.5	63.9	61.5	67.9		
	ESR2013	23.1	27.1	25.0	28.6	28.7	32.2	30.7	28.5	35.1	40.5	47.0	45.6	48.1	49.9	53.0	60.2	57.0	65.6	63.9	61.6	67.8	5.3 (4.7; 6.0)	2004-2024
																							4.7 (3.0; 6.4)	2004-2012
																							9.9 (6.7; 13.1)	2013-2016
																							3.7 (2.0; 5.5)	2017-2024
65+	**N**	300	321	340	318	370	398	397	429	481	532	585	578	643	699	724	749	738	883	945	978	967		
	CR	28.7	30.5	32.2	30.1	35.0	37.3	36.9	39.5	43.5	47.5	51.5	50.1	55.1	59.2	60.5	61.8	60.0	71.1	74.9	76.3	74.2		
	ESR2013	28.6	30.3	31.8	29.4	34.3	36.0	36.5	38.5	43.3	48.4	50.8	50.8	54.6	59.0	60.9	62.2	60.2	70.6	75.5	76.9	74.2	5.4 (5.0; 5.8)	2004-2024
																							5.9 (5.2; 6.7)	2004-2016
																							4.6 (3.5; 5.7)	2017-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



3.1. Melanoma prevalence: by region

3.1.1. Melanoma prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	1,933	8,077	13,111	16,059	17,553	2,195	10,008	17,552	22,536	25,624
	CR	33.2	138.5	224.9	275	301	36.6	166.9	292.8	376	427
	ESR2013	34.2	142.7	231.9	284.1	310.6	35.4	161.8	283.7	363.7	413.0
Brussels	**N**	147	513	825	1,071	1,197	136	563	1,008	1,333	1,580
	CR	23.9	83.4	134.1	174.0	194.5	21.2	87.9	157.4	208.1	246.7
	ESR2013	34.7	123.0	199.1	257.9	288.2	25.6	104.4	187.2	248.1	295.8
Flanders	**N**	1,272	5,439	8,585	10,302	11,207	1,505	6,920	11,782	14,755	16,592
	CR	37.4	160.0	252.5	303.0	329.6	43.4	199.7	340.0	425.8	478.9
	ESR2013	36.5	156.3	246.8	296.1	322.0	41.1	189.2	321.6	401.5	450.6
Wallonia	**N**	514	2,125	3,701	4,686	5,149	554	2,525	4,762	6,448	7,452
	CR	28.3	117.1	203.9	258.2	283.7	29.3	133.6	251.9	341.1	394.3
	ESR2013	29.7	123.0	214.7	272.0	299.5	28.3	129.6	244.9	331.5	382.3



4.1. Melanoma survival: by region

4.1.1. Melanoma survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024				
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All ages 15+**	35,618	98.5% (98.3%; 98.7%)	96.2% (95.9%; 96.6%)	95.6% (95.1%; 96.2%)	96.3% (94.7%; 97.8%)
Males						
Belgium	**All ages 15+**	15,814	97.9% (97.6%; 98.3%)	95.3% (94.6%; 95.9%)	94.8% (93.8%; 95.7%)	95.9% (93.3%; 98.6%)
	15-49	2,873	98.9% (98.5%; 99.3%)	96.9% (96.2%; 97.6%)	95.8% (95.0%; 96.7%)	95.0% (93.7%; 96.3%)
	50-64	5,105	98.3% (97.9%; 98.7%)	95.7% (95.0%; 96.4%)	94.9% (94.0%; 95.8%)	94.2% (92.4%; 96.0%)
	65+	7,865	97.4% (96.7%; 98.0%)	94.4% (93.3%; 95.6%)	94.4% (92.6%; 96.2%)	97.7% (92.2%; 103.5%)
Brussels	**All ages 15+**	1,043	97.7% (96.2%; 99.2%)	96.5% (93.9%; 99.2%)	94.5% (90.2%; 99.0%)	100.0% (90.2%; 110.7%)
	15-49	163	98.3% (96.3%; 100.4%)	95.8% (92.4%; 99.3%)	93.4% (88.8%; 98.1%)	95.0% (90.3%; 99.8%)
	50-64	309	97.6% (95.6%; 99.6%)	96.4% (93.6%; 99.3%)	94.6% (90.7%; 98.7%)	93.5% (85.5%; 102.2%)
	65+	572	97.5% (95.1%; 100.0%)	96.7% (92.3%; 101.3%)	94.6% (87.4%; 102.4%)	103.5% (86.6%; 123.6%)
Flanders	**All ages 15+**	10,276	97.9% (97.4%; 98.3%)	94.9% (94.1%; 95.7%)	94.1% (92.9%; 95.2%)	94.6% (91.2%; 98.2%)
	15-49	1,739	99.0% (98.5%; 99.5%)	96.9% (96.0%; 97.8%)	95.9% (94.8%; 97.0%)	94.8% (93.2%; 96.5%)
	50-64	3,384	98.3% (97.8%; 98.8%)	95.4% (94.6%; 96.3%)	94.6% (93.5%; 95.7%)	92.8% (90.6%; 95.2%)
	65+	5,169	97.2% (96.5%; 98.0%)	93.8% (92.4%; 95.3%)	93.1% (91.0%; 95.3%)	96.0% (89.0%; 103.6%)
Wallonia	**All ages 15+**	4,498	98.1% (97.4%; 98.7%)	95.9% (94.7%; 97.1%)	96.3% (94.6%; 98.1%)	97.4% (93.1%; 102.0%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-49	971	98.8% (98.0%; 99.5%)	97.1% (96.0%; 98.4%)	96.0% (94.5%; 97.6%)	95.3% (93.2%; 97.5%)
	50-64	1,413	98.4% (97.6%; 99.3%)	96.1% (94.7%; 97.5%)	95.6% (93.8%; 97.4%)	97.1% (94.0%; 100.3%)
	65+	2,126	97.5% (96.3%; 98.8%)	95.2% (92.9%; 97.5%)	97.0% (93.6%; 100.6%)	98.9% (89.4%; 109.5%)
Females						
Belgium	**All ages 15+**	19,804	98.9% (98.7%; 99.1%)	97.0% (96.6%; 97.5%)	96.3% (95.7%; 97.0%)	96.6% (94.8%; 98.5%)
	15-49	5,760	99.7% (99.5%; 99.9%)	98.8% (98.4%; 99.1%)	98.2% (97.8%; 98.6%)	97.4% (96.7%; 98.1%)
	50-64	6,412	99.4% (99.1%; 99.6%)	98.4% (98.0%; 98.8%)	98.0% (97.5%; 98.6%)	97.2% (95.9%; 98.4%)
	65+	7,675	97.9% (97.3%; 98.5%)	94.6% (93.5%; 95.7%)	93.5% (91.9%; 95.2%)	95.8% (90.9%; 100.9%)
Brussels	**All ages 15+**	1,197	98.3% (97.1%; 99.5%)	97.6% (95.6%; 99.7%)	97.9% (94.8%; 101.0%)	106.0% (97.5%; 115.1%)
	15-49	312	99.8% (99.1%; 100.4%)	98.2% (96.6%; 99.9%)	98.5% (96.8%; 100.2%)	98.8% (96.7%; 100.9%)
	50-64	334	99.2% (98.0%; 100.4%)	98.4% (96.5%; 100.3%)	98.7% (96.4%; 101.0%)	98.2% (93.2%; 103.6%)
	65+	555	96.9% (94.5%; 99.3%)	96.8% (92.7%; 101.1%)	97.1% (90.8%; 103.8%)	114.0% (95.7%; 135.8%)
Flanders	**All ages 15+**	13,201	99.0% (98.7%; 99.3%)	97.1% (96.6%; 97.7%)	96.5% (95.7%; 97.3%)	94.7% (92.3%; 97.1%)
	15-49	3,642	99.7% (99.5%; 99.9%)	98.8% (98.4%; 99.2%)	98.2% (97.7%; 98.8%)	97.1% (96.3%; 98.0%)
	50-64	4,443	99.6% (99.3%; 99.8%)	98.5% (98.0%; 99.0%)	98.0% (97.3%; 98.6%)	96.9% (95.5%; 98.3%)
	65+	5,144	98.0% (97.3%; 98.7%)	94.7% (93.4%; 96.0%)	94.0% (92.0%; 96.0%)	90.8% (84.7%; 97.4%)
Wallonia	**All ages 15+**	5,414	98.8% (98.3%; 99.3%)	96.7% (95.7%; 97.6%)	95.6% (94.3%; 96.9%)	98.5% (95.7%; 101.3%)
	15-49	1,810	99.7% (99.4%; 100.0%)	98.8% (98.2%; 99.3%)	98.2% (97.4%; 99.0%)	97.7% (96.2%; 99.1%)
	50-64	1,636	98.9% (98.3%; 99.5%)	98.2% (97.3%; 99.1%)	98.0% (96.8%; 99.2%)	97.5% (94.8%; 100.3%)
	65+	1,978	97.8% (96.6%; 99.0%)	93.5% (91.1%; 95.9%)	91.2% (87.8%; 94.8%)	100.6% (92.6%; 109.3%)

4.2. Melanoma survival: by tumour stage

4.2.1. Melanoma survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
cStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	35,618	98.5% (98.3%; 98.7%)	97.1% (96.8%; 97.4%)	96.2% (95.9%; 96.6%)	95.8% (95.4%; 96.3%)	95.6% (95.1%; 96.2%)	96.3% (94.7%; 97.8%)
Males							
Total	15,814	97.9% (97.6%; 98.3%)	96.2% (95.7%; 96.7%)	95.3% (94.6%; 95.9%)	95.0% (94.2%; 95.8%)	94.8% (93.8%; 95.7%)	95.9% (93.3%; 98.6%)
I	11,649	100.9% (100.7%; 101.2%)	101.4% (101.0%; 101.8%)	102.2% (101.7%; 102.7%)	103.2% (102.6%; 103.9%)	103.8% (103.0%; 104.7%)	108.4% (105.5%; 111.3%)
II	3,045	96.7% (95.7%; 97.7%)	89.5% (87.9%; 91.1%)	83.9% (81.9%; 86.0%)	80.2% (77.8%; 82.6%)	77.4% (74.7%; 80.3%)	67.9% (61.4%; 75.2%)
III	262	85.5% (80.8%; 90.4%)	77.3% (71.6%; 83.4%)	72.8% (66.5%; 79.7%)	69.0% (62.0%; 76.9%)	62.9% (54.2%; 73.0%)	53.8% (41.6%; 69.7%)
IV	296	64.0% (58.4%; 70.0%)	51.1% (45.2%; 57.7%)	41.2% (35.2%; 48.2%)	38.6% (32.3%; 46.1%)	36.7% (30.1%; 44.7%)	25.9% (17.2%; 39.0%)
X/NA	729	72.6% (69.2%; 76.2%)	65.0% (61.2%; 69.0%)	60.8% (56.7%; 65.2%)	57.2% (52.7%; 62.1%)	57.0% (52.1%; 62.3%)	56.0% (45.2%; 69.3%)
Females							
Total	19,804	98.9% (98.7%; 99.1%)	97.9% (97.5%; 98.2%)	97.0% (96.6%; 97.5%)	96.5% (96.0%; 97.1%)	96.3% (95.7%; 97.0%)	96.6% (94.8%; 98.5%)
I	15,710	100.7% (100.5%; 100.8%)	101.2% (101.0%; 101.4%)	101.4% (101.1%; 101.8%)	101.9% (101.5%; 102.3%)	102.3% (101.8%; 102.9%)	103.8% (101.9%; 105.6%)
II	3,118	97.6% (96.7%; 98.5%)	91.5% (90.0%; 93.1%)	87.0% (85.1%; 89.0%)	83.0% (80.6%; 85.3%)	80.2% (77.5%; 82.9%)	76.0% (70.1%; 82.4%)
III	253	89.4% (85.2%; 93.9%)	76.4% (70.7%; 82.6%)	70.6% (64.2%; 77.6%)	64.7% (57.7%; 72.6%)	62.6% (55.1%; 71.1%)	58.3% (47.3%; 71.8%)
IV	208	63.1% (56.5%; 70.4%)	46.8% (40.0%; 54.8%)	39.1% (32.2%; 47.4%)	32.2% (24.9%; 41.7%)	33.2% (25.7%; 42.9%)	25.0% (15.8%; 39.5%)
X/NA	627	75.9% (72.4%; 79.5%)	70.1% (66.2%; 74.3%)	64.6% (60.3%; 69.2%)	62.6% (57.9%; 67.6%)	61.5% (56.5%; 66.9%)	58.3% (49.4%; 68.8%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.2. Melanoma survival by pathological stage (pStage) and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
pStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	35,618	98.5% (98.3%; 98.7%)	97.1% (96.8%; 97.4%)	96.2% (95.9%; 96.6%)	95.8% (95.4%; 96.3%)	95.6% (95.1%; 96.2%)	96.3% (94.7%; 97.8%)
Males							
Total	15,814	97.9% (97.6%; 98.3%)	96.2% (95.7%; 96.7%)	95.3% (94.6%; 95.9%)	95.0% (94.2%; 95.8%)	94.8% (93.8%; 95.7%)	95.9% (93.3%; 98.6%)
I	11,392	101.0% (100.7%; 101.2%)	101.5% (101.1%; 101.8%)	102.3% (101.8%; 102.8%)	103.4% (102.7%; 104.1%)	104.1% (103.2%; 104.9%)	108.6% (105.7%; 111.5%)
II	2,533	95.2% (93.9%; 96.4%)	89.5% (87.7%; 91.3%)	84.3% (82.0%; 86.6%)	81.4% (78.8%; 84.2%)	79.2% (76.1%; 82.5%)	68.8% (61.1%; 77.5%)
III	1,126	95.5% (94.0%; 97.1%)	86.3% (83.9%; 88.8%)	80.3% (77.5%; 83.3%)	74.9% (71.6%; 78.4%)	70.9% (67.2%; 74.8%)	67.2% (61.4%; 73.6%)
IV	148	71.1% (63.8%; 79.4%)	51.9% (43.8%; 61.4%)	46.4% (38.1%; 56.5%)	42.8% (34.3%; 53.4%)	39.9% (31.1%; 51.1%)	38.4% (26.6%; 55.5%)
X/NA	801	71.3% (68.0%; 74.7%)	62.8% (59.1%; 66.6%)	58.2% (54.3%; 62.5%)	54.7% (50.4%; 59.3%)	54.4% (49.8%; 59.5%)	50.7% (40.4%; 63.5%)
Females							
Total	19,804	98.9% (98.7%; 99.1%)	97.9% (97.5%; 98.2%)	97.0% (96.6%; 97.5%)	96.5% (96.0%; 97.1%)	96.3% (95.7%; 97.0%)	96.6% (94.8%; 98.5%)
I	15,448	100.6% (100.5%; 100.8%)	101.2% (100.9%; 101.4%)	101.5% (101.2%; 101.8%)	102.0% (101.6%; 102.4%)	102.4% (101.9%; 102.9%)	104.0% (102.2%; 105.9%)
II	2,649	97.1% (96.0%; 98.2%)	91.2% (89.5%; 92.9%)	86.9% (84.7%; 89.1%)	83.1% (80.5%; 85.8%)	80.4% (77.5%; 83.5%)	76.0% (69.5%; 83.1%)
III	1,031	96.7% (95.3%; 98.1%)	88.9% (86.6%; 91.2%)	83.5% (80.7%; 86.4%)	78.6% (75.3%; 82.0%)	76.7% (73.1%; 80.4%)	73.2% (66.1%; 81.1%)
IV	102	73.0% (64.5%; 82.6%)	60.8% (51.3%; 72.1%)	55.8% (45.8%; 68.1%)	43.4% (32.0%; 59.0%)	39.6% (28.1%; 56.0%)	27.7% (14.2%; 54.0%)
X/NA	690	73.8% (70.4%; 77.4%)	67.1% (63.3%; 71.2%)	61.3% (57.2%; 65.7%)	59.5% (55.1%; 64.3%)	58.3% (53.6%; 63.5%)	54.5% (46.2%; 64.2%)

4.2.3. Melanoma survival by stage and sex: number at risk and net survival probabilities, 2015-2024

Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	35,618	98.5% (98.3%; 98.7%)	97.1% (96.8%; 97.4%)	96.2% (95.9%; 96.6%)	95.8% (95.4%; 96.3%)	95.6% (95.1%; 96.2%)	96.3% (94.7%; 97.8%)
Males							
Total	15,814	97.9% (97.6%; 98.3%)	96.2% (95.7%; 96.7%)	95.3% (94.6%; 95.9%)	95.0% (94.2%; 95.8%)	94.8% (93.8%; 95.7%)	95.9% (93.3%; 98.6%)
I	11,377	101.0% (100.8%; 101.2%)	101.5% (101.1%; 101.9%)	102.4% (101.8%; 102.9%)	103.5% (102.8%; 104.1%)	104.2% (103.3%; 105.0%)	108.6% (105.7%; 111.6%)
II	2,446	96.6% (95.5%; 97.8%)	91.2% (89.4%; 93.0%)	86.1% (83.8%; 88.4%)	83.2% (80.5%; 85.9%)	81.0% (77.8%; 84.4%)	70.5% (62.6%; 79.4%)
III	1,114	95.7% (94.2%; 97.3%)	86.3% (83.9%; 88.8%)	80.9% (78.0%; 83.8%)	75.4% (72.0%; 78.8%)	71.5% (67.8%; 75.4%)	68.4% (62.5%; 74.9%)
IV	360	66.6% (61.6%; 72.0%)	51.5% (46.1%; 57.4%)	42.2% (36.7%; 48.5%)	40.0% (34.2%; 46.7%)	37.3% (31.2%; 44.5%)	29.3% (20.7%; 41.5%)
X/NA	705	71.8% (68.3%; 75.4%)	64.0% (60.1%; 68.1%)	59.9% (55.7%; 64.4%)	56.3% (51.7%; 61.3%)	55.9% (51.0%; 61.4%)	53.2% (42.2%; 67.2%)
Females							
Total	19,804	98.9% (98.7%; 99.1%)	97.9% (97.5%; 98.2%)	97.0% (96.6%; 97.5%)	96.5% (96.0%; 97.1%)	96.3% (95.7%; 97.0%)	96.6% (94.8%; 98.5%)
I	15,432	100.7% (100.5%; 100.8%)	101.2% (101.0%; 101.4%)	101.5% (101.2%; 101.9%)	102.0% (101.6%; 102.4%)	102.5% (101.9%; 103.0%)	104.1% (102.3%; 106.0%)
II	2,585	97.8% (96.7%; 98.8%)	92.4% (90.7%; 94.1%)	88.3% (86.1%; 90.5%)	84.7% (82.1%; 87.4%)	82.0% (79.0%; 85.1%)	77.6% (71.0%; 84.8%)
III	1,037	96.5% (95.0%; 97.9%)	88.6% (86.3%; 90.9%)	83.3% (80.5%; 86.2%)	78.2% (74.9%; 81.7%)	76.2% (72.6%; 80.0%)	72.9% (65.8%; 80.7%)
IV	250	66.6% (60.6%; 73.1%)	51.0% (44.7%; 58.3%)	43.0% (36.5%; 50.7%)	34.5% (27.3%; 43.4%)	33.5% (26.2%; 42.8%)	22.2% (13.2%; 37.4%)
X/NA	617	75.6% (72.1%; 79.3%)	69.7% (65.8%; 73.9%)	64.1% (59.7%; 68.7%)	62.3% (57.6%; 67.3%)	61.1% (56.1%; 66.6%)	57.8% (48.8%; 68.3%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Melanoma survival trends: by tumour stage

5.1.1. Melanoma survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	**All**	4,005	94.9% (94.0%; 95.7%)	87.1% (85.7%; 88.5%)	84.0% (82.2%; 85.8%)	6,050	96.9% (96.4%; 97.5%)	92.6% (91.7%; 93.5%)	90.5% (89.3%; 91.7%)
	I	1,963	100.1% (99.5%; 100.7%)	100.5% (99.3%; 101.7%)	100.2% (98.5%; 102.1%)	3,479	100.2% (99.8%; 100.5%)	100.0% (99.3%; 100.6%)	99.7% (98.7%; 100.7%)
	II	726	96.9% (94.9%; 99.0%)	77.8% (73.7%; 82.0%)	70.5% (65.6%; 75.9%)	851	96.5% (94.7%; 98.4%)	82.5% (79.0%; 86.2%)	76.2% (71.7%; 81.0%)
	III	277	85.1% (80.7%; 89.8%)	60.8% (54.8%; 67.5%)	52.5% (46.2%; 59.7%)	263	92.6% (89.2%; 96.2%)	77.3% (71.9%; 83.2%)	66.2% (59.8%; 73.2%)
	IV	144	59.2% (51.5%; 68.1%)	27.6% (20.9%; 36.4%)	23.3% (16.8%; 32.1%)	126	63.6% (55.5%; 72.9%)	44.0% (35.5%; 54.5%)	31.3% (23.6%; 41.6%)
	X/NA	918	89.7% (87.4%; 92.0%)	82.2% (79.0%; 85.4%)	77.7% (73.8%; 81.7%)	1,364	92.6% (91.0%; 94.3%)	87.3% (84.9%; 89.7%)	85.6% (82.8%; 88.6%)
2010-2014	**All**	5,114	95.5% (94.8%; 96.3%)	90.3% (89.2%; 91.5%)	89.0% (87.5%; 90.5%)	7,100	98.0% (97.6%; 98.5%)	95.4% (94.6%; 96.2%)	93.7% (92.6%; 94.7%)
	I	3,039	100.8% (100.3%; 101.2%)	101.7% (100.8%; 102.7%)	103.1% (101.7%; 104.5%)	4,708	100.5% (100.2%; 100.7%)	101.1% (100.5%; 101.6%)	101.2% (100.3%; 102.1%)
	II	842	94.3% (92.2%; 96.5%)	79.3% (75.6%; 83.1%)	72.1% (67.6%; 76.8%)	983	96.7% (94.9%; 98.5%)	85.9% (82.7%; 89.4%)	78.6% (74.2%; 83.1%)
	III	348	92.5% (89.3%; 95.7%)	70.1% (64.9%; 75.7%)	62.6% (56.8%; 69.0%)	341	94.5% (91.8%; 97.3%)	81.6% (77.1%; 86.4%)	71.4% (66.1%; 77.2%)
	IV	128	50.8% (42.6%; 60.6%)	27.3% (20.2%; 37.0%)	20.7% (14.1%; 30.4%)	92	69.9% (60.9%; 80.2%)	40.4% (31.2%; 52.4%)	36.3% (27.1%; 48.8%)
	X/NA	788	84.9% (82.2%; 87.7%)	77.1% (73.5%; 80.8%)	75.5% (71.4%; 79.9%)	1,002	91.4% (89.4%; 93.4%)	87.3% (84.6%; 90.0%)	85.6% (82.4%; 88.9%)
2015-2019	**All**	6,989	97.7% (97.2%; 98.2%)	94.3% (93.3%; 95.2%)	93.4% (92.1%; 94.6%)	9,230	99.0% (98.7%; 99.4%)	97.0% (96.4%; 97.7%)	96.3% (95.4%; 97.2%)
	I	4,917	101.0% (100.7%; 101.4%)	102.1% (101.3%; 102.8%)	103.6% (102.4%; 104.8%)	7,095	100.7% (100.5%; 100.8%)	101.4% (100.9%; 101.8%)	102.2% (101.5%; 102.9%)
	II	1,108	97.1% (95.5%; 98.8%)	85.5% (82.3%; 88.9%)	79.2% (75.0%; 83.6%)	1,282	97.7% (96.3%; 99.2%)	88.3% (85.4%; 91.2%)	82.6% (78.8%; 86.5%)

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	492	93.6% (91.1%; 96.3%)	78.7% (74.5%; 83.1%)	68.7% (63.9%; 74.0%)	460	96.7% (94.7%; 98.8%)	83.4% (79.4%; 87.6%)	77.2% (72.6%; 82.2%)
	IV	159	65.0% (57.6%; 73.3%)	36.5% (29.1%; 45.7%)	33.4% (25.9%; 43.2%)	99	65.0% (55.9%; 75.6%)	39.5% (30.2%; 51.8%)	28.8% (19.5%; 42.5%)
	X/NA	376	73.9% (69.3%; 78.8%)	59.7% (54.2%; 65.8%)	55.6% (49.4%; 62.6%)	332	80.8% (76.3%; 85.4%)	71.0% (65.5%; 77.0%)	67.4% (61.2%; 74.3%)
2020-2024	All	8,972	98.1% (97.7%; 98.6%)	96.2% (95.4%; 97.1%)	96.5% (95.1%; 98.0%)	10,747	98.8% (98.5%; 99.2%)	97.1% (96.4%; 97.8%)	96.2% (95.1%; 97.4%)
	I	6,560	101.0% (100.7%; 101.3%)	102.7% (102.0%; 103.4%)	105.1% (103.8%; 106.4%)	8,467	100.7% (100.5%; 100.9%)	101.7% (101.3%; 102.2%)	102.7% (101.8%; 103.6%)
	II	1,342	96.1% (94.4%; 97.7%)	86.7% (83.5%; 90.0%)	84.0% (78.7%; 89.6%)	1,309	97.7% (96.2%; 99.2%)	87.9% (84.6%; 91.3%)	79.7% (74.4%; 85.4%)
	III	622	97.4% (95.6%; 99.2%)	82.8% (79.0%; 86.9%)	72.7% (66.5%; 79.4%)	577	96.2% (94.3%; 98.3%)	83.3% (79.3%; 87.4%)	74.3% (68.3%; 80.8%)
	IV	201	67.9% (61.2%; 75.2%)	47.5% (39.9%; 56.5%)	40.3% (31.1%; 52.2%)	151	67.5% (60.0%; 75.9%)	45.9% (37.5%; 56.2%)	37.6% (27.9%; 50.6%)
	X/NA	329	69.3% (64.2%; 74.9%)	59.9% (53.7%; 66.8%)	55.9% (47.7%; 65.3%)	286	69.6% (64.1%; 75.4%)	55.1% (48.5%; 62.6%)	53.5% (45.4%; 63.0%)



6.1. Melanoma mortality: by region

6.1.1. Melanoma mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	0	0	2	4	2	2	13	15	16	27	24	21	23	29	14	3	195	3.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.1]	[0.5]	[0.5]	[3.3]	[3.7]	[4.3]	[8.5]	[9.0]	[10.3]	[18.4]	[36.4]	[44.7]	[49.5]	[3.4]	(3.2; 4.2)
Brussels	0	0	0	0	0	0	0	0	0	0	1	0	2	1	1	2	3	1	1	0	12	3.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[0.0]	[6.9]	[4.7]	[5.9]	[15.8]	[37.3]	[20.0]	[43.4]	[0.0]	[2.0]	(1.4; 5.3)
Flanders	0	0	0	0	0	0	1	3	1	2	10	13	10	17	16	13	16	19	10	3	134	4.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[0.5]	[0.9]	[4.4]	[5.4]	[4.4]	[8.7]	[9.7]	[10.0]	[19.4]	[35.3]	[48.1]	[75.6]	[4.0]	(3.4; 4.8)
Wallonia	0	0	0	0	0	0	1	1	1	0	2	2	4	9	7	6	4	9	3	0	49	3.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.9]	[0.9]	[0.0]	[1.6]	[1.6]	[3.4]	[8.9]	[8.2]	[9.9]	[11.6]	[43.0]	[36.5]	[0.0]	[2.7]	(2.2; 4.0)
Females																						
Belgium	0	0	0	0	1	0	2	2	3	5	7	8	15	12	11	23	26	21	13	6	155	2.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.5]	[0.5]	[0.8]	[1.4]	[1.8]	[2.0]	[3.9]	[3.5]	[3.7]	[9.4]	[14.9]	[15.7]	[18.3]	[28.8]	[2.6]	(1.9; 2.7)
Brussels	0	0	0	0	0	0	0	0	0	1	0	0	1	2	1	1	2	2	0	0	10	2.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[0.0]	[0.0]	[3.3]	[8.0]	[4.7]	[5.6]	[15.6]	[20.4]	[0.0]	[0.0]	[1.6]	(0.7; 3.2)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	1	0	2	1	3	4	5	6	13	5	10	16	12	11	11	5	105	2.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[0.5]	[1.4]	[1.9]	[2.2]	[2.5]	[5.7]	[2.5]	[5.7]	[10.6]	[11.0]	[12.9]	[25.0]	[40.8]	[3.1]	(2.1; 3.1)
Wallonia	0	0	0	0	0	0	0	1	0	0	2	2	1	5	0	6	12	8	2	1	40	1.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[0.0]	[1.6]	[1.6]	[0.8]	[4.5]	[0.0]	[7.7]	[23.1]	[20.7]	[9.4]	[15.4]	[2.1]	(1.3; 2.5)

7.1. Melanoma mortality trends: by region

7.1.1. Melanoma mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	129	149	146	149	168	163	167	179	155	196	171	169	183	176	189	153	173	174	171	195		
	CR	2.5	2.9	2.8	2.9	3.2	3.1	3.1	3.3	2.9	3.6	3.1	3.1	3.3	3.2	3.4	2.7	3.1	3.1	3.0	3.4		
	ESR2013	3.2	3.7	3.5	3.3	3.9	3.7	3.9	4.1	3.5	4.3	3.6	3.5	3.8	3.5	3.8	3.1	3.3	3.4	3.3	3.7	0.1 (-0.5; 0.8)	2004-2023
																						3.6 (0.8; 6.4)	2004-2009
																						-1.1 (-1.9; -0.2)	2010-2023
Brussels	**N**	8	10	11	12	10	7	12	11	11	7	11	8	11	13	13	11	9	11	13	12		
	CR	1.7	2.1	2.2	2.4	2.0	1.4	2.3	2.0	2.0	1.2	1.9	1.4	1.9	2.2	2.2	1.9	1.5	1.8	2.2	2.0		
	ESR2013	1.9	2.6	3.3	3.4	2.4	1.7	3.3	3.4	3.3	2.0	3.0	2.0	3.5	3.5	3.6	3.1	2.4	3.0	3.4	3.4	1.4 (-0.4; 3.4)	2004-2023
Flanders	**N**	72	101	104	85	113	109	111	118	100	132	107	119	117	120	128	99	103	121	107	134		
	CR	2.4	3.4	3.5	2.8	3.7	3.6	3.6	3.8	3.2	4.2	3.4	3.7	3.7	3.7	3.9	3.0	3.1	3.7	3.2	4.0		
	ESR2013	3.0	4.1	4.0	3.1	4.4	4.2	4.2	4.3	3.6	4.7	3.6	4.0	3.8	3.9	4.1	3.2	3.2	3.7	3.3	4.1	0.2 (-0.8; 1.2)	2004-2023
																						4.8 (0.4; 9.4)	2004-2009
																						-1.3 (-2.6; 0.0)	2010-2023
Wallonia	**N**	49	38	31	52	45	47	44	50	44	57	53	42	55	43	48	43	61	42	51	49		
	CR	3.0	2.3	1.9	3.1	2.7	2.8	2.6	2.9	2.6	3.3	3.0	2.4	3.1	2.4	2.7	2.4	3.4	2.4	2.8	2.7		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
ESR2013	3.9	3.3	2.5	3.8	3.5	3.4	3.5	3.8	3.4	4.2	3.7	3.0	3.7	2.9	3.2	2.8	4.0	2.9	3.1	3.1	-0.5 (-1.6; 0.6)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Melanoma mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	145	131	120	153	150	153	149	173	136	185	185	157	153	150	166	152	149	164	166	155		
	CR	2.7	2.5	2.2	2.8	2.8	2.8	2.7	3.1	2.4	3.3	3.3	2.8	2.7	2.6	2.9	2.6	2.6	2.8	2.8	2.6		
	ESR2013	2.7	2.5	2.2	2.8	2.7	2.7	2.6	3.0	2.3	3.2	3.1	2.6	2.5	2.4	2.6	2.4	2.3	2.6	2.4	2.3	-0.5 (-1.3; 0.2)	2004-2023
Brussels	**N**	18	8	12	13	11	11	11	15	13	18	16	10	10	11	17	8	7	9	11	10		
	CR	3.5	1.5	2.3	2.4	2.0	2.0	2.0	2.6	2.2	3.0	2.7	1.7	1.6	1.8	2.8	1.3	1.1	1.4	1.8	1.6		
	ESR2013	3.7	1.8	2.6	2.9	2.2	2.3	2.1	3.1	2.4	3.3	3.0	1.8	1.9	2.0	3.0	1.3	1.4	1.9	1.8	2.0	-2.5 (-4.4; -0.6)	2004-2023
Flanders	**N**	95	77	71	103	94	108	89	110	86	121	128	103	101	105	99	116	106	108	105	105		
	CR	3.1	2.5	2.3	3.3	3.0	3.4	2.8	3.4	2.7	3.7	3.9	3.2	3.1	3.2	3.0	3.5	3.2	3.2	3.1	3.1		
	ESR2013	3.1	2.6	2.3	3.3	2.9	3.2	2.7	3.3	2.4	3.5	3.6	2.9	2.8	2.9	2.6	3.1	2.7	2.8	2.6	2.6	-0.3 (-1.3; 0.7)	2004-2023
Wallonia	**N**	32	46	37	37	45	34	49	48	37	46	41	44	42	34	50	28	36	47	50	40		
	CR	1.8	2.6	2.1	2.1	2.5	1.9	2.7	2.7	2.0	2.5	2.2	2.4	2.3	1.8	2.7	1.5	1.9	2.5	2.7	2.1		
	ESR2013	1.9	2.7	2.1	2.1	2.5	1.9	2.6	2.6	2.0	2.4	2.0	2.3	2.1	1.8	2.4	1.4	1.9	2.4	2.4	1.9	-0.7 (-2.1; 0.6)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026